Objective: To investigate the risk and pattern of tumors in italian neurofibromatosis type 1 (NF1) patients. Materials and Methods: A retrospective single institution case review of 711 patients (seen between March 1992 and February 2018) with NF1 was conducted to identify individuals with diagnoses of both NF1 and neoplasm. NF1-associated tumors have been collected and analyzed. Results: We identified 221 tumors in 191 subjects with a percentage of 26.9%, diagnosed at a median age of 32.5 years (range, 0.6-70.1 years); 111 of these patients were females (58%) and all were fol-lowed up for a median of 5.3 years. The cumulative risks for tumor in patients with NF1 by the ages of 30 and 60 years were 10% and 42.5%, respectively. In our patients with tumor, overall survival at 70 years was significantly shorter than in those without it (50% vs 95%, P<0.0001). We found an unequivocally increased incidence for breast cancer in females (33 cases observed). Conclusions: Tumors that develop in patients with NF1 are heterogeneous, our data are consistent with other reports suggesting an increase in some cancers risk among these individuals, therefore systematic medical follow-up in people with NF1 is important.

Tumors in patients with neurofibromatosis type 1: a single-center retrospective study / Roberti, V.; Miraglia, E.; Laghi, A.; Iacovino, C.; Moliterni, E.; Giustini, S.. - In: LA CLINICA TERAPEUTICA. - ISSN 1972-6007. - 173:2(2022), pp. 135-140. [10.7417/CT.2022.2407]

Tumors in patients with neurofibromatosis type 1: a single-center retrospective study

Roberti V.
Primo
;
Miraglia E.
Secondo
;
Laghi A.;Iacovino C.;Moliterni E.
Penultimo
;
Giustini S.
Ultimo
2022

Abstract

Objective: To investigate the risk and pattern of tumors in italian neurofibromatosis type 1 (NF1) patients. Materials and Methods: A retrospective single institution case review of 711 patients (seen between March 1992 and February 2018) with NF1 was conducted to identify individuals with diagnoses of both NF1 and neoplasm. NF1-associated tumors have been collected and analyzed. Results: We identified 221 tumors in 191 subjects with a percentage of 26.9%, diagnosed at a median age of 32.5 years (range, 0.6-70.1 years); 111 of these patients were females (58%) and all were fol-lowed up for a median of 5.3 years. The cumulative risks for tumor in patients with NF1 by the ages of 30 and 60 years were 10% and 42.5%, respectively. In our patients with tumor, overall survival at 70 years was significantly shorter than in those without it (50% vs 95%, P<0.0001). We found an unequivocally increased incidence for breast cancer in females (33 cases observed). Conclusions: Tumors that develop in patients with NF1 are heterogeneous, our data are consistent with other reports suggesting an increase in some cancers risk among these individuals, therefore systematic medical follow-up in people with NF1 is important.
2022
cancer; epidemiology; neurofibro-min; neurofibromatosis; adolescent; adult; aged; child; child, preschool; female; humans; incidence; infant; Italy; middle aged; retrospective studies; young adult; neurofibromatosis 1
01 Pubblicazione su rivista::01a Articolo in rivista
Tumors in patients with neurofibromatosis type 1: a single-center retrospective study / Roberti, V.; Miraglia, E.; Laghi, A.; Iacovino, C.; Moliterni, E.; Giustini, S.. - In: LA CLINICA TERAPEUTICA. - ISSN 1972-6007. - 173:2(2022), pp. 135-140. [10.7417/CT.2022.2407]
File allegati a questo prodotto
File Dimensione Formato  
Roberti_Tumors in patients_2022.pdf

accesso aperto

Note: https://clinicaterapeutica.it/ojs/index.php/1/article/view/481
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 981.84 kB
Formato Adobe PDF
981.84 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1629221
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact